Peer-influenced content. Sources you trust. No registration required. This is HCN.

Cancer Therapy AdvisorKRAS G12C Mutations in Metastatic Colorectal Cancer: Questions Remain

Studies suggest that G12C mutations occur in 3% to 8% of total colorectal cancer (CRC) cases and constitute 6% to 17% of KRAS mutations. Having a G12C mutation may be an adverse prognostic factor in mCRC, but confounding factors may be more responsible for differences in treatment outcomes than the G12C mutation itself. The two conflicting presentations at the ESMO World Congress on Gastrointestinal Cancer highlight the critical need to define the prognostic significance of the G12C mutation and the resulting treatment implications more precisely.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form